Microbot Medical Stock

Microbot Medical Debt

The Debt of Microbot Medical (MBOT) as of Aug 11, 2026 is -78.30 M USD. In the previous year, Debt was -6.23 M USD — a change of 1,157.16% (lower).

Debt

-78.30 MUSD

YoY

1,157.16%

Last updated:

In 2026, Microbot Medical's total debt was -78.30 M USD, a 1,157.16% change from the -6.23 M USD total debt recorded in the previous year.

Access this data via the Eulerpool API

Microbot Medical Stock analysis

What does Microbot Medical do? Microbot Medical Inc. is a leading company in the development of microrobots for the medical field. The company was established in 2010 and is headquartered in Hingham, Massachusetts. Microbot Medical Inc. believes that the future of medicine lies in robotics and specializes in developing innovative solutions for complex surgical procedures and minimally invasive interventions. The company's business model is based on the development and commercialization of intelligent microrobots that will enable more precise and gentle surgical interventions. From the beginning, the company has focused on two main areas: the development of robot-assisted systems for neurosurgical procedures and the development of solutions for gastroenterology applications. In the field of neurosurgical procedures, Microbot Medical Inc. has developed the LIBERTY robot for market readiness. This robot is designed to assist surgeons during neurosurgical procedures that require increased precision and effectiveness. The robot aids the surgeon in navigating difficult-to-access areas of the brain and can help minimize the risk of tissue damage. Microbot Medical Inc. is also a leader in the development of robots in the gastroenterology field. The company has introduced the SELF-TESTER robot, which is capable of performing endoscopies in a more comfortable and painless manner. The SELF-TESTER is navigated through the digestive system and can help diagnose diseases such as cancer or inflammations in the gastrointestinal tract more effectively. Furthermore, Microbot Medical Inc. conducts research and development activities in the field of cardiovascular surgery. The company is working on a solution that allows doctors to implant aortic valves minimally invasively. The goal is to create an alternative to traditional open-heart surgery. The company has also signed a letter of intent with Cardiovascular Systems Inc. to jointly bring a new product to market that has the potential to further accelerate the minimally invasive aortic valve implantation procedure. In recent years, Microbot Medical Inc. has received several awards and recognitions, including an award from Frost & Sullivan in the category of "New Product Innovation." The company has also formed important partnerships with other leaders in the medical technology field to support the development and commercialization of its products. In conclusion, Microbot Medical Inc. is one of the leading providers of intelligent robots for the medical field and will play an important role in the development of advanced technologies that contribute to making surgical interventions more effective and safer in the coming years. The company is committed to driving innovations in medical technology and has already made a name for itself by successfully developing products in various areas. Microbot Medical is one of the most popular companies on Eulerpool.

Debt Details

Understanding Microbot Medical's Debt Structure

Microbot Medical's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Microbot Medical's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Microbot Medical’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Microbot Medical’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Microbot Medical stock

Debt of Microbot Medical is -78.30 M USD in 2026.

Debt of Microbot Medical changed from -6.23 M USD to -78.30 M USD, representing a 1,157.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Microbot Medical since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Microbot Medical historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Microbot Medical

All Key Metrics — Microbot Medical